Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Wang, J L ^a,b   Shamah, S M ^c   Sun, A X ^d   Waldman, I D ^e   Haggarty, S J ^a,b   Perlis, R H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c X Body Biosciences   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYT1L PROTEIN; PROTEIN; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ARTICLE; BIOSENSOR; BIPOLAR DISORDER; BIPOLAR I DISORDER; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; DRUG RESPONSE; FIBROBLAST; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; MENTAL DISEASE; MOLECULAR IMAGING; NERVE CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; SKIN CELL; ACTION POTENTIAL; CELL LABELING; CLINICAL ARTICLE; CRYSTAL; FOLLOW UP; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NERVE FIBER GROWTH; NEURAL STEM CELL; OPTICAL BIOSENSOR; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY;

EID: 84907361242     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.72     Document Type: Article

References (35)

1. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196.
3. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar disord 2013; 15: 1-44.
4. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395.
5. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275-280.
6. Shi Y, Kirwan P, Smith J, Robinson HPC, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci 2012; 15: 477-486.
7. Wang Y, Dolmetsch R. In vitro human corticogenesis. Neuron 2013; 77: 379-381.
8. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
9. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 2011; 228-231.
10. Ladewig J, Mertens J, Kesavan J, Doerr J, Poppe D, Glaue F et al. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat Methods 2012; 9: 575-578.
11. Qiang L, Fujita R, Abeliovich A. Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron 2013; 78: 957-969.
12. Faull RJ, Ginsberg MH. Inside-out signaling through integrins. J Am Soc Nephrol 1996; 7: 1091-1097.
13. Bova MP, Nguyen L, Wallace W, Garrido C, Xu Y-Z, Semko C et al. A label-free approach to identify inhibitors of alpha4beta7-mediated cell adhesion to MadCAM. J Biomol Screen 2011; 16: 536-544.
14. Shamah SM, Cunningham BT. Label-free cell-based assays using photonic crystal optical biosensors. Analyst 2011; 136: 1090-1102.
15. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942-947.
16. Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) Report. PLoS One 2013; 8: e65636.
17. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS et al. Lentivirusdelivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
18. Cohen J, Cohen P, West SG, Aiken LS. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, 3rd edn. Lawrence Erlbaum Associates: Mahwah, NJ, USA, 2002.
19. Self SG, Liang KY. Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under nonstandard conditions. J Am Stat Asso 1987; 82: 398.
20. Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002; 63: 1171-1178.
21. Grof P, Duffy A, Alda M, Hajek T. Lithium response across generations. Acta Psychiatr Scand 2009; 120: 378-385.
22. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
23. Bora E, Fornito A, Yücel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 2010; 67: 1097-1105.
24. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
25. Fan Y, Abrahamsen G, Mills R, Calderón CC, Tee JY, Leyton L et al. Focal adhesion dynamics are altered in schizophrenia. Biol Psychiatry 2013; 74: 418-426.
26. Nacher J, Guirado R, Castillo-Gómez E. Structural plasticity of interneurons in the adult brain: role of PSA-NCAM and implications for psychiatric disorders. Neurochem Res 2013; 38: 1122-1133.
27. Varea E, Guirado R, Gilabert-Juan J, Martí U, Castillo- Gómez E, Blasco-Ibáñez JM et al. Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. J Psychiatr Res 2012; 46: 189-197.
28. Sprooten E, Fleming KM, Thomson PA, Bastin ME, Whalley HC, Hall J et al. White matter integrity as an intermediate phenotype: exploratory genome-wide association analysis in individuals at high risk of bipolar disorder. Psychiatry Res 2013; 206: 223-231.
29. Hill MJ, Jeffries AR, Dobson RJ, Price J, Bray NJ. Knockdown of the psychosis susceptibility gene ZNF804A alters expression of genes involved in cell adhesion. Hum Mol Genet 2012; 21: 1018-1024.
30. Blanpied TA, Ehlers MD. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Biol Psychiatry 2004; 55: 1121-1127.
31. Cingolani LA, Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat Rev Neurosci 2008; 9: 344-356.
32. Han K, Holder JL Jr, Schaaf CP, Lu H, Chen H, Kang H et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013; 503: 72-77.
33. Takeichi M, Abe K. Synaptic contact dynamics controlled by cadherin and catenins. Trends Cell Biol 2005; 15: 216-221.
34. Williams RSB, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295.
35. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3b in cellular signaling. Prog Neurobiol 2001; 65: 391-426.